Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm
Nuclear Medicine Review · 31.01.2022 · 25 (1) · 54-61
DOI: 10.5603/nmr.a2022.0016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuclear Medicine Review, online erschienen am 31.01.2022. Verfasst von Barbara Bober und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland. barbara.bober@tlen.pl. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland. barbara.bober@tlen.pl.
- Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland.
- Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.
Zitieren
APA
Bober, B., Saracyn, M., Lubas, A., Kolodziej, M., Brodowska-Kania, D., Kapusta, W., & Kaminski, G. (2022). Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm. Nuclear Medicine Review, 25(1), 54-61. https://doi.org/10.5603/nmr.a2022.0016
Vancouver
Bober B, Saracyn M, Lubas A, Kolodziej M, Brodowska-Kania D, Kapusta W, et al. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm. Nuclear Medicine Review. 2022;25(1):54-61. doi:10.5603/nmr.a2022.0016
BibTeX
@article{Bober2022,
author = {Bober, Barbara and Saracyn, Marek and Lubas, Arkadiusz and Kolodziej, Maciej and Brodowska-Kania, Dorota and Kapusta, Waldemar and Kaminski, Grzegorz},
title = {Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm},
journal = {Nuclear Medicine Review},
year = {2022},
volume = {25},
number = {1},
pages = {54--61},
doi = {10.5603/nmr.a2022.0016}
}
EUVIMED